Editas Medicine (EDIT) and Genevant Sciences said Monday they will combine Editas' CRISPR Cas12a genome editing systems with Genevant's LNP technology in the development of in vivo gene editing medicines for two targets in Editas' upregulation strategy.
Genevant granted Editas a nonexclusive license to exploit mRNA-CRISPR Cas12a-LNP products for the targets, with Genevant eligible to receive up to $238 million in upfront and contingent milestone payments, according to the companies.
Price: 3.8100, Change: +0.05, Percent Change: +1.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.